Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy.

Mayra Alejandra Mafla-EspañaMaría Dolores TorregrosaManel Beamud-CortésLorena Bermell-MarcoJosé Rubio-BrionesOmar Cauli

Published in: Biomolecules (2023)

Further research into the role of androstenedione should be evaluated in follow-up studies in order to recommend its use as a suitable biomarker of frailty syndrome in prostate cancer patients.

Keyphrases

prostate cancer
community dwelling
radical prostatectomy
case control
middle aged
benign prostatic hyperplasia
stem cells
cell therapy